Recombinant DNA Advisory Committee - 2/10-11/92 
I. CALL TO ORDER AND OPENING REMARKS 
Dr. Barbara Murray (Chair) called the meeting to order at 9:00 a.m. on February 10, 1992, 
and welcomed the members of the Recombinant DNA Advisory Committee (RAC). A 
quorum was present for the meeting. Dr. B. Murray stated that notice of the meeting was 
duly published in the Federal Register in accordance with the requirements of the National 
Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules. 
She reminded the committee that it serves as an advisor to the Director, NIH, and that its 
actions are not binding. It was noted that this meeting would be open to the public. 
Discussion of agenda items was designated in the following order: primary and secondary 
reviewers on each item; other members of the RAC; ad hoc consultants to the RAC; NIH 
staff members; other government agencies; members of the public who submitted written 
comments; and other members of the public. Dr. B. Murray welcomed Dr. LeRoy 
Walters, the ad hoc consultant to the committee who will soon become a RAC member. 
Dr. B. Murray thanked Drs. Mclvor, Gellert, R. Murray, and Mr. Mannix for their 
dedication, yeoman efforts, and service to the RAC. 
II. MINUTES OF THE OCTOBER 7-8, 1991, MEETING 
Dr. Doi stated that the minutes of the October 7-8, 1991, RAC meeting accurately 
reflected the discussion and actions. Mr. Barton concurred. The minutes were approved 
by the committee by a vote of 14 in favor, 0 opposed, and no abstentions. 
III. COMMENTS OF DR. GERARD McGARRITY 
Dr. McGarrity reflected on his term as Chair of the RAC. On June 5-6, 1980, he attended 
his first meeting of the RAC. "Hot" topics were whether people could grow recombinant 
organisms in volumes larger than 10 liters, and how to handle purified recombinant DNA. 
As the responsibilities of the RAC evolved, no untoward events have occurred. Obviously, 
investigators have chosen to adhere to the rules and guidelines developed by the RAC. 
He commended the review process followed by the committee and stated that "the RAC 
has been a true lighthouse in guiding this trip of recombinant organisms." 
Dr. McGarrity concluded his remarks by thanking the NIH Directors (past and present), 
the RAC, the Human Gene Therapy Subcommittee (HGTS), and specific individuals for 
making his appointment to the RAC a high point to his professional and personal career. 
IV. PROPOSED AMENDMENT TO APPENDIX D-XV OF THE NIH GUIDELINES 
REGARDING A HUMAN GENE THERAPY PROTOCOL ENTITLED: TREATMENT OF 
SEVERE COMBINED IMMUNODEFICIENCY DISEASE (SCID) DUE TO ADENOSINE 
DEAMINASE (ADA) DEFICIENCY WITH AUTOLOGOUS LYMPHOCYTES 
[316] 
Recombinant DNA Research, Volume 15 
